N. Ostermann

发表

Insights into the phosphoryltransfer mechanism of human thymidylate kinase gained from crystal structures of enzyme complexes along the reaction coordinate.

I. Schlichting, N. Ostermann, R. Brundiers, 2000, Structure.

The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.

E. Jacoby, N. Ostermann, U. Hassiepen, 2013, Journal of medicinal chemistry.

Gift from Nature: Cyclomarin A Kills Mycobacteria and Malaria Parasites by Distinct Modes of Action

M. Schirle, N. Ostermann, B. Gerhartz, 2015, Chembiochem : a European journal of chemical biology.

Electrochemical N2 splitting at well-defined metal complexes

N. Ostermann, Inke Siewert, 2019, Current Opinion in Electrochemistry.

Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.

N. Ostermann, T. Kanazawa, D. Rigel, 2014, ACS medicinal chemistry letters.

Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.

N. Ostermann, A. Vulpetti, B. Gerhartz, 2017, Journal of medicinal chemistry.

Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D.

N. Ostermann, A. Vulpetti, A. Mac Sweeney, 2018, ACS medicinal chemistry letters.

trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.

N. Ostermann, E. Francotte, C. Ehrhardt, 2015, Bioorganic & medicinal chemistry letters.

Exploring T Cell Reactivity to Gliadin in Young Children with Newly Diagnosed Celiac Disease

N. Ostermann, K. Seidl, B. Gerhartz, 2014, Autoimmune diseases.

Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.

D. E. Clark, N. Ostermann, U. Hassiepen, 2014, Bioorganic & medicinal chemistry letters.

Small-molecule factor D inhibitors targeting the alternative complement pathway.

N. Ostermann, C. Durand, A. Vulpetti, 2016, Nature chemical biology.

Structures of human thymidylate kinase in complex with prodrugs: implications for the structure-based design of novel compounds.

C. Meier, C. Monnerjahn, N. Ostermann, 2003, Biochemistry.

Modifying Human Thymidylate Kinase to Potentiate Azidothymidine Activation*

I. Schlichting, N. Ostermann, R. Brundiers, 1999, The Journal of Biological Chemistry.

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

W. Jahnke, P. Couttet, N. Ostermann, 2020, Journal of medicinal chemistry.

Structural basis for efficient phosphorylation of 3'-azidothymidine monophosphate by Escherichia coli thymidylate kinase.

I. Schlichting, N. Ostermann, R. Brundiers, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.

D. E. Clark, C. Higgs, N. Ostermann, 2012, Bioorganic & medicinal chemistry letters.

Potentiating AZT activation: structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP.

I. Schlichting, N. Ostermann, R. Brundiers, 2000, Journal of molecular biology.

A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.

Eric Vangrevelinghe, Markus Krömer, Edgar Jacoby, 2013, Journal of medicinal chemistry.

Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.

Karen Anderson, Anna Vulpetti, Ulrich Hommel, 2017, Journal of medicinal chemistry.

Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.

N. Ostermann, U. Hassiepen, U. Eidhoff, 2006, Journal of molecular biology.

Crystal structure of an activation intermediate of cathepsin E.

N. Ostermann, B. Gerhartz, J. Eder, 2004, Journal of molecular biology.

Design and Biochemical Characterization of Peptidic Inhibitors of the Myb/p300 Interaction.

T. Vorherr, N. Ostermann, P. Ertl, 2023, Biochemistry.

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

N. Ostermann, C. Schnell, Toshio Shimizu, 2022, Cancer discovery.

Redox-Active Heteroatom-Functionalized Polyacetylenes.

N. Ostermann, M. Ferguson, E. Rivard, 2021, Angewandte Chemie.

Preclinical target validation using patient-derived cells

Arthur S Slutsky, J. Isaac, B. Pollock, 2015, Nature Reviews Drug Discovery.

Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models

D. Erdmann, N. Ostermann, C. Schnell, 2021, Poster Presentations - Proffered Abstracts.

New N-2-labelled fluorescent derivatives of guanosine nucleotides and their interaction with GTP-binding proteins

N. Ostermann, R. Goody, A. Wittinghofer, 1999 .

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.

N. Ostermann, R. Wilcken, S. Brachmann, 2022, Journal of medicinal chemistry.